IL10 rs1800896 基因变异预测炎症性肠病患者的生化缓解 接受生物治疗的患者
Michela Helga Falzone1, Davide Giuseppe Ribaldone1,2, Martina Buglione1
1Department of Medical Sciences, University of Turin, Turin, Italy.
Immunology
|October 30, 2025
概括
细胞因子基因中的遗传变异会影响炎症性肠病 (IBD) 的进展和治疗反应. 在IL10中特定的单核酸变异 (SNV) 与接受向治疗的IBD患者的缓解有关.
科学领域:
- 遗传学 遗传学是一种遗传学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 细胞因子基因中的单核酸变体 (SNV) 涉及调节疾病进程和炎症性肠病 (IBD) 治疗结果.
- 了解这些遗传关联可能会为IBD患者个性化治疗策略.
研究的目的:
- 研究四种特定的细胞因子SNV与IBD患者的临床特征和向治疗反应之间的关系.
- 确定基因分析是否可以预测克罗恩病 (CD) 和性结肠炎 (UC) 的治疗疗效和疾病表型.
主要方法:
- 在接受分子向治疗的197名IBD患者 (142个CD,55个UC) 中,对四种SNV (TNFA rs1800629,TGFB rs1800471,IL6 rs1800795,IL10 rs1800896) 的基因定型.
- 基于C-反应蛋白和便calprotectin水平的12个月生化缓解的评估.
- 统计分析,包括多变量分析,以评估SNV,临床表型和治疗反应之间的关联.
主要成果:
- IL6 rs1800795 C等位基因与诊断时的年龄较小有关 (p=0.049).
- 与UC患者相比,TNFA rs1800629 A基因基因在CD患者中更为普遍 (p=0.036).
- IL10 rs1800896变异基因基因与12个月内实现生化缓解有显著的关联 (OR=2.15,p=0.041),在多变量分析中仍然显著 (aOR=4.15,p=0.007).
结论:
- 细胞因子SNVs,特别是IL10 rs1800896,可以作为IBD治疗反应的预测标记.
- 这些SNV的基因定型可能有助于识别具有侵略性疾病表型的患者,并优化IBD个性化治疗计划.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
Inflammatory Bowel Disease IV: Pharmacological Management
463
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
463
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
423
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
423
Inflammatory Bowel Disease II: Crohn's Disease
943
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
943
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
626
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
626


